{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:54:45Z","timestamp":1790319285120,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00520-020-05707-3","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T22:09:35Z","timestamp":1598566175000},"page":"6129-6143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors"],"prefix":"10.1007","volume":"28","author":[{"given":"Michael","family":"Dougan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada G.","family":"Blidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Girotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie R.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"5707_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","volume":"8","author":"M Dougan","year":"2017","unstructured":"Dougan M (2017) Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 8:1547. https:\/\/doi.org\/10.3389\/fimmu.2017.01547","journal-title":"Front Immunol"},{"issue":"12","key":"5707_CR2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","volume":"6","author":"Y Eshet","year":"2018","unstructured":"Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G (2018) Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res 6(12):1453\u20131458. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0659","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"5707_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","volume":"23","author":"K Reynolds","year":"2018","unstructured":"Reynolds K, Thomas M, Dougan M (2018) Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 23(9):991\u2013997. https:\/\/doi.org\/10.1634\/theoncologist.2018-0174","journal-title":"Oncologist"},{"issue":"2","key":"5707_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","volume":"14","author":"E Raschi","year":"2019","unstructured":"Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F (2019) Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA Adverse Event Reporting System. Target Oncol 14(2):205\u2013221. https:\/\/doi.org\/10.1007\/s11523-019-00632-w","journal-title":"Target Oncol"},{"issue":"1","key":"5707_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y (2019) Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118. https:\/\/doi.org\/10.1186\/s40425-019-0604-2","journal-title":"J Immunother Cancer"},{"issue":"6","key":"5707_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 40(6):511\u2013523. https:\/\/doi.org\/10.1016\/j.it.2019.04.002","journal-title":"Trends Immunol"},{"issue":"4","key":"5707_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395\u2013401. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv227","journal-title":"J Crohns Colitis"},{"issue":"5","key":"5707_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","volume":"41","author":"JH Chen","year":"2017","unstructured":"Chen JH, Pezhouh MK, Lauwers GY, Masia R (2017) Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 41(5):643\u2013654. https:\/\/doi.org\/10.1097\/PAS.0000000000000829","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"5707_CR9","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283\u20132289. https:\/\/doi.org\/10.1200\/JCO.2005.04.5716","journal-title":"J Clin Oncol"},{"issue":"1","key":"5707_CR10","doi-asserted-by":"publisher","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG (2018) Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3(1):e000278. https:\/\/doi.org\/10.1136\/esmoopen-2017-000278","journal-title":"ESMO Open"},{"issue":"1","key":"5707_CR11","doi-asserted-by":"publisher","first-page":"e1524695","DOI":"10.1080\/2162402X.2018.1524695","volume":"8","author":"DY Wang","year":"2018","unstructured":"Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB (2018) Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 8(1):e1524695. https:\/\/doi.org\/10.1080\/2162402X.2018.1524695","journal-title":"Oncoimmunology"},{"issue":"8","key":"5707_CR12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A (2018) Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24(8):1695\u20131705","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"5707_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/CMR.0000000000000484","volume":"28","author":"A Sokal","year":"2018","unstructured":"Sokal A, de Chou CS, Delyon J, Roche B, Lourenco N, Lebbe C, Baroudjian B, PATIO group (2018) Enteritis without colitis in patients treated with immune checkpoint inhibitors: a tricky diagnosis. Melanoma Res 28(5):483\u2013484. https:\/\/doi.org\/10.1097\/CMR.0000000000000484","journal-title":"Melanoma Res"},{"issue":"6","key":"5707_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","volume":"28","author":"RHL Yip","year":"2018","unstructured":"Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM (2018) Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res 28(6):645\u2013647. https:\/\/doi.org\/10.1097\/CMR.0000000000000502","journal-title":"Melanoma Res"},{"issue":"2","key":"5707_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000491862","volume":"11","author":"Y Nishimura","year":"2018","unstructured":"Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T, Otsuka F (2018) Severe gastritis after administration of nivolumab and ipilimumab. Case Rep Oncol 11(2):549\u2013556. https:\/\/doi.org\/10.1159\/000491862","journal-title":"Case Rep Oncol"},{"key":"5707_CR16","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.14309\/crj.2017.57","volume":"4","author":"J Boike","year":"2017","unstructured":"Boike J, Dejulio T (2017) Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J 4:e57. https:\/\/doi.org\/10.14309\/crj.2017.57","journal-title":"ACG Case Rep J"},{"key":"5707_CR17","doi-asserted-by":"publisher","first-page":"3406437","DOI":"10.1155\/2018\/3406437","volume":"2018","author":"R Celli","year":"2018","unstructured":"Celli R, Kluger HM, Zhang X (2018) Anti-PD-1 therapy-associated perforating colitis. Case Rep Gastrointest Med 2018:3406437\u20133406433. https:\/\/doi.org\/10.1155\/2018\/3406437","journal-title":"Case Rep Gastrointest Med"},{"issue":"21","key":"5707_CR18","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361(21):2066\u20132078. https:\/\/doi.org\/10.1056\/NEJMra0804647","journal-title":"N Engl J Med"},{"issue":"1","key":"5707_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A (2018) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37. https:\/\/doi.org\/10.1186\/s40425-018-0346-6","journal-title":"J Immunother Cancer"},{"issue":"17","key":"5707_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"5707_CR21","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"issue":"1","key":"5707_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"8","key":"5707_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"19","key":"5707_CR24","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb\u00e9 C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845\u20131855. https:\/\/doi.org\/10.1056\/NEJMoa1611299","journal-title":"N Engl J Med"},{"issue":"14","key":"5707_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebb\u00e9 C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"issue":"34","key":"5707_CR26","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A (2017) Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 35(34):3851\u20133858. https:\/\/doi.org\/10.1200\/JCO.2016.72.1985","journal-title":"J Clin Oncol"},{"issue":"22","key":"5707_CR27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"issue":"14","key":"5707_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, DF MD, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"8","key":"5707_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andr\u00e9 T (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773\u2013779. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901","journal-title":"J Clin Oncol"},{"issue":"4","key":"5707_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","volume":"5","author":"M Garcia-Neuer","year":"2017","unstructured":"Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA (2017) Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 5(4):286\u2013291. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0302","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"5707_CR31","doi-asserted-by":"publisher","first-page":"W468","DOI":"10.2214\/AJR.12.9751","volume":"200","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N (2013) Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 200(5):W468\u2013W474. https:\/\/doi.org\/10.2214\/AJR.12.9751","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"5707_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00261-015-0560-3","volume":"41","author":"AR Barina","year":"2016","unstructured":"Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY) 41(2):207\u2013214. https:\/\/doi.org\/10.1007\/s00261-015-0560-3","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"5707_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y (2018) Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 6(1):95. https:\/\/doi.org\/10.1186\/s40425-018-0411-1","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5707_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-019-0524-1","volume":"7","author":"E Bello","year":"2019","unstructured":"Bello E, Cohen JV, Mino-Kenudson M, Dougan M (2019) Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer 7(1):41. https:\/\/doi.org\/10.1186\/s40425-019-0524-1","journal-title":"J Immunother Cancer"},{"issue":"6","key":"5707_CR35","doi-asserted-by":"publisher","first-page":"e1128611","DOI":"10.1080\/2162402X.2015.1128611","volume":"5","author":"K Lankes","year":"2016","unstructured":"Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, G\u00f6hl J, Schuler G, Neurath MF, Hohenberger W, Heinzerling L (2016) Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 5(6):e1128611. https:\/\/doi.org\/10.1080\/2162402X.2015.1128611","journal-title":"Oncoimmunology"},{"issue":"1","key":"5707_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000497155","volume":"12","author":"C Zhou","year":"2019","unstructured":"Zhou C, Klionsky Y, Treasure ME, Bruno DS (2019) Pembrolizumab-induced immune-mediated colitis in a patient with concurrent Clostridium difficile infection. Case Rep Oncol 12(1):164\u2013170. https:\/\/doi.org\/10.1159\/000497155","journal-title":"Case Rep Oncol"},{"issue":"4","key":"5707_CR37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","volume":"88","author":"NM Gentile","year":"2013","unstructured":"Gentile NM, D'Souza A, Fujii LL, Wu TT, Murray JA (2013) Association between ipilimumab and celiac disease. Mayo Clin Proc 88(4):414\u2013417. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.015","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"5707_CR38","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11(7):e0160221. https:\/\/doi.org\/10.1371\/journal.pone.0160221","journal-title":"PLoS One"},{"issue":"1","key":"5707_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y (2018) Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6(1):142. https:\/\/doi.org\/10.1186\/s40425-018-0461-4","journal-title":"J Immunother Cancer"},{"issue":"5","key":"5707_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J (2017) Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 66(5):581\u2013592. https:\/\/doi.org\/10.1007\/s00262-017-1962-6","journal-title":"Cancer Immunol Immunother"},{"key":"5707_CR41","doi-asserted-by":"publisher","first-page":"216641","DOI":"10.1136\/bcr-2016-216641","volume":"2016","author":"AH Hsieh","year":"2016","unstructured":"Hsieh AH, Ferman M, Brown MP, Andrews JM (2016) Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep 2016:216641. https:\/\/doi.org\/10.1136\/bcr-2016-216641","journal-title":"BMJ Case Rep"},{"issue":"24","key":"5707_CR42","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-15-2471","volume":"21","author":"E Arriola","year":"2015","unstructured":"Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C (2015) Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 21(24):5642\u20135643. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2471","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5707_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","volume":"6","author":"DH Johnson","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A (2018) Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103. https:\/\/doi.org\/10.1186\/s40425-018-0412-0","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5707_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y (2019) Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93. https:\/\/doi.org\/10.1186\/s40425-019-0577-1","journal-title":"J Immunother Cancer"},{"issue":"6","key":"5707_CR45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68(6):1181\u20131190. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"issue":"1","key":"5707_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","volume":"23","author":"SG Bernardo","year":"2013","unstructured":"Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, Chang R, Friedlander P, Saenger YM (2013) Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23(1):47\u201354. https:\/\/doi.org\/10.1097\/CMR.0b013e32835c7e68","journal-title":"Melanoma Res"},{"issue":"21","key":"5707_CR47","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, Hermes B, \u00c7ay \u015eenler F, Cs\u0151szi T, F\u00fcl\u00f6p A, Rodr\u00edguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM, KEYNOTE-407 Investigators (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"issue":"22","key":"5707_CR48","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"issue":"12","key":"5707_CR49","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"5707_CR50","doi-asserted-by":"publisher","first-page":"175883591983082","DOI":"10.1177\/1758835919830826","volume":"11","author":"MS Pelster","year":"2019","unstructured":"Pelster MS, Amaria RN (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1758835919830826. https:\/\/doi.org\/10.1177\/1758835919830826","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5707_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","volume":"41","author":"J Everett","year":"2017","unstructured":"Everett J, Srivastava A, Misdraji J (2017) Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 41(1):134\u2013137. https:\/\/doi.org\/10.1097\/PAS.0000000000000759","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"5707_CR52","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39(8):1075\u20131084. https:\/\/doi.org\/10.1097\/PAS.0000000000000453","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"5707_CR53","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM (2018) Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 31(6):965\u2013973. https:\/\/doi.org\/10.1038\/s41379-018-0013-y","journal-title":"Mod Pathol"},{"issue":"8","key":"5707_CR54","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233\u20132240. https:\/\/doi.org\/10.1007\/s10620-012-2140-5","journal-title":"Dig Dis Sci"},{"issue":"4","key":"5707_CR55","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs 31(4):1071\u20131077. https:\/\/doi.org\/10.1007\/s10637-013-9939-6","journal-title":"Investig New Drugs"},{"key":"5707_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","volume":"81","author":"I Sp\u00e4nkuch","year":"2017","unstructured":"Sp\u00e4nkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T (2017) Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 81:203\u2013205. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.018","journal-title":"Eur J Cancer"},{"issue":"1","key":"5707_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-019-0532-1","volume":"7","author":"HC Zhang","year":"2019","unstructured":"Zhang HC, Luo W, Wang Y (2019) Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. J Immunother Cancer 7(1):47. https:\/\/doi.org\/10.1186\/s40425-019-0532-1","journal-title":"J Immunother Cancer"},{"issue":"17","key":"5707_CR58","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15(17):5591\u20135598. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5707_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/his.13963","volume":"76","author":"ML Zhang","year":"2020","unstructured":"Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V (2020) Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 76(2):233\u2013243. https:\/\/doi.org\/10.1111\/his.13963","journal-title":"Histopathology"},{"issue":"1","key":"5707_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MOG.0000000000000493","volume":"35","author":"DR Nemakayala","year":"2019","unstructured":"Nemakayala DR, Cash BD (2019) Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? Curr Opin Gastroenterol 35(1):58\u201362. https:\/\/doi.org\/10.1097\/MOG.0000000000000493","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"5707_CR61","doi-asserted-by":"publisher","first-page":"e000451","DOI":"10.1136\/jitc-2019-000451","volume":"8","author":"MJ Mooradian","year":"2020","unstructured":"Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, Johnson DB, Sullivan RJ, Dougan M (2020) Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 8(1):e000451. https:\/\/doi.org\/10.1136\/jitc-2019-000451","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5707_CR62","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","volume":"7","author":"MS Hughes","year":"2019","unstructured":"Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M (2019) Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 7(1):292. https:\/\/doi.org\/10.1186\/s40425-019-0756-0","journal-title":"J Immunother Cancer"},{"issue":"5","key":"5707_CR63","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1111\/ajco.12651","volume":"13","author":"NT Hillock","year":"2017","unstructured":"Hillock NT, Heard S, Kichenadasse G, Hill CL, Andrews J (2017) Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac J Clin Oncol 13(5):e284\u2013e290. https:\/\/doi.org\/10.1111\/ajco.12651","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"5707_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00008390-200204000-00010","volume":"12","author":"I Panagiotou","year":"2002","unstructured":"Panagiotou I, Brountzos EN, Bafaloukos D, Stoupis C, Brestas P, Kelekis DA (2002) Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res 12(2):169\u2013173. https:\/\/doi.org\/10.1097\/00008390-200204000-00010","journal-title":"Melanoma Res"},{"issue":"1","key":"5707_CR65","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, S\u00e9gui B (2017) TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun 8(1):2256. https:\/\/doi.org\/10.1038\/s41467-017-02358-7","journal-title":"Nat Commun"},{"issue":"7756","key":"5707_CR66","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569(7756):428\u2013432. https:\/\/doi.org\/10.1038\/s41586-019-1162-y","journal-title":"Nature"},{"issue":"2","key":"5707_CR67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","volume":"47","author":"JR Maneiro","year":"2017","unstructured":"Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47(2):149\u2013156. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.007","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5707_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-015-3115-7","volume":"35","author":"Y Chen","year":"2016","unstructured":"Chen Y, Sun J, Yang Y, Huang Y, Liu G (2016) Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. Clin Rheumatol 35(1):1\u201318. https:\/\/doi.org\/10.1007\/s10067-015-3115-7","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5707_CR69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41591-018-0305-2","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR (2019) Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188. https:\/\/doi.org\/10.1038\/s41591-018-0305-2","journal-title":"Nat Med"},{"issue":"3","key":"5707_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/apt.14173","volume":"46","author":"SP Costello","year":"2017","unstructured":"Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM (2017) Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 46(3):213\u2013224. https:\/\/doi.org\/10.1111\/apt.14173","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"5707_CR71","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/apt.14201","volume":"46","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46(5):479\u2013493. https:\/\/doi.org\/10.1111\/apt.14201","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"5707_CR72","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, UNITI\u2013IM-UNITI Study Group (2016) Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375(20):1946\u20131960. https:\/\/doi.org\/10.1056\/NEJMoa1602773","journal-title":"N Engl J Med"},{"issue":"6","key":"5707_CR73","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6):1120\u20131133 e17. https:\/\/doi.org\/10.1016\/j.cell.2017.07.024","journal-title":"Cell"},{"issue":"9","key":"5707_CR74","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"N Engl J Med"},{"issue":"1","key":"5707_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065","journal-title":"Cell"},{"issue":"1\u20132","key":"5707_CR76","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"issue":"12","key":"5707_CR77","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1136\/gutjnl-2014-308541","volume":"64","author":"S Zeissig","year":"2015","unstructured":"Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, Laerdahl JK, Stade B, Forster M, Schreiber S, Weir D, Leichtner AM, Franke A, Blumberg RS (2015) Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut 64(12):1889\u20131897. https:\/\/doi.org\/10.1136\/gutjnl-2014-308541","journal-title":"Gut"},{"issue":"12","key":"5707_CR78","doi-asserted-by":"publisher","first-page":"1410141","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Sch\u00e4ffer AA, Gr\u00fcning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LSK, Sansom DM, Grimbacher B (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410141\u20131410146. https:\/\/doi.org\/10.1038\/nm.3746","journal-title":"Nat Med"},{"issue":"6204","key":"5707_CR79","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","volume":"345","author":"HS Kuehn","year":"2014","unstructured":"Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623\u20131627. https:\/\/doi.org\/10.1126\/science.1255904","journal-title":"Science"},{"issue":"11","key":"5707_CR80","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.4049\/jimmunol.158.11.5091","volume":"158","author":"EA Tivol","year":"1997","unstructured":"Tivol EA, Boyd SD, McKeon S, Borriello F, Nickerson P, Strom TB, Sharpe AH (1997) CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 158(11):5091\u20135094","journal-title":"J Immunol"},{"issue":"1","key":"5707_CR81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","volume":"25","author":"SR Schoenfeld","year":"2020","unstructured":"Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL (2020) Diagnosis and management of rare immune-related adverse events. Oncologist 25(1):6\u201314. https:\/\/doi.org\/10.1634\/theoncologist.2019-0083","journal-title":"Oncologist"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05707-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T11:47:48Z","timestamp":1696592868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05707-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5707"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05707-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB, RA, JC, TC, PG, DG, and VRS have no conflict of interest to declare. MD reports grants from Novartis and other (SAB) from Neoleukin Therapeutics, personal fees from Partner Therapeutics, personal fees from Tillotts Pharma, and grants from Genentech outside the submitted work. MG reports consultant work with Bristol Myers Squibb (BMS) and AstraZeneca outside the submitted work. IG reports other (Stock Ownership) from Pfizer Inc. and personal fees from CytomX Inc. outside the submitted work. DBJ reports other (advisory board) from Array Biopharma, grants and other (advisory board) from BMS, other (advisory board) from Jansen, grants from Incyte, other (advisory board) from Merck, and other (advisory board) from Novartis outside the submitted work. In addition, DBJ has a patent co-inventor on use of CTLA-4 agonist for IAEs pending. BLR reports personal fees and other (advisory board) from Merck and Co; grants, personal fees, and other (advisory board) from BMS; grants, personal fees, and other (advisory board) from Roche South Africa; and personal fees and other (advisory board) from AstraZeneca during the conduct of the study. MSA reports personal fees from Gilead, grants from Pfizer, and personal fees from Abbvie outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}